Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: Nested cohort within a multicenter clinical trial

Journal of Infection and Chemotherapy

Volumn 19, Issue 3, 2013, Pages 472-479

  Fujita, Jiro ^a   Niki, Yoshihito ^b   Kadota, Jun Ichi ^c   Yanagihara, Katsunori ^d   Kaku, Mitsuo ^e   Watanabe, Akira ^f   Aoki, Nobuki ^g   Hori, Seiji ^h   Tanigawara, Yusuke ⁱ   Cash, Haley L ^a   Kohno, Shigeru ^d  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OITA UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f TOHOKU UNIVERSITY   (Japan)

^g Shinrakuen Hospital   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ KEIO UNIVERSITY   (Japan)

Author keywords

Gyrase; Levofloxacin resistant Streptococcus pneumoniae; Sitafloxacin STFX); Topoisomerase IV

Indexed keywords

BACTERIAL ANTIGEN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; QUINOLONE; SITAFLOXACIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; GENE MUTATION; GYRA GENE; GYRB GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PARE GENE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; URINALYSIS;

EID: 84879240218     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0514-4     Document Type: Article

References (23)

1. Appelbaum PC. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin Infect Dis. 2002;34:1613-20.
2. File TM Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect. 2006;12(suppl 3):31-41.
3. Keating GM. Sitafloxacin: in bacterial infections. Drugs. 2011;71:731-44.
4. Saito A, Miki F, Oizumi K, Rikitomi N, Watanabe A, Koga H, et al. Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: report of the Committee for the Respiratory System, Japan Society of Chemotherapy. J Infect Chemother. 1999;5:110-23.
5. National Committee for Clinical Laboratory Standards (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Sixth edition. NCCLS document M7-A6. NCCLS, Wayne, PA
6. Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother. 1999;43:329-34.
7. Saito A, Watanabe A, Aoki N, Niki Y, Kohno S, Kaku M, et al. Phase III double-blind comparative study of sitafloxacin versus tosufoxacin in patients with community-acquired pneumonia (in Japanese). Jpn J Chemother. 2008;56(suppl 1):49-62.
8. Kobayashi H, Watanabe A, Nakata K, Wada K, Niki Y, Kohono S. Double-blind comparative study of sitafloxacin versus levofloxacin in patients with respiratory tract infection (in Japanese). Jpn J Chemother. 2008;56(suppl 1):36-48.
9. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother. 2009;64(suppl 1):i3-10.
10. Ubukata K. Problems associated with high prevalence of multidrug-resistant bacteria in patients with community-acquired infections. J Infect Chemother. 2003;9:285-91.
11. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50(suppl 1):25-37.
12. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother. 2003;52:944-52.
13. Yokota S, Sato K, Kuwahara O, Habadera S, Tsukamoto N, Ohuchi H, et al. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother. 2002;46:3311-5.
14. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis. 2005;41:118-21.
15. Broskey J, Coleman K, Gwynn MN, McCloskey L, Traini C, Voelker L, et al. Efflux and target mutations as quinolones resistance mechanisms in clinical isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2000;45(suppl 1):95-9.
16. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. 2005;40:225-35.
17. Jolley A, Andrews JM, Brenwald N, Wise R. The in vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother. 1993;32:757-63.
18. Jones ME, Sahm DF, Martin N, Scheuring S, Heisig P, Thornsberry C, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during 1997-1998 respiratory season. Antimicrob Agents Chemother. 2000;44:462-6.
19. Browne FA, Bozdogan B, Clark C, Kelly LM, Ednie L, Kosowska K, et al. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents. Antimicrob Agents Chemother. 2003;47:3815-24.
20. Okumura R, Hirata T, Onodera Y, Hoshino K, Otani T, Yamamoto T. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008;62:98-104.
21. Yokota S, Ohkoshi Y, Fujii N. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Diagn Microbiol Infect Dis. 2009;65:76-80.
22. Touyama M, Higa F, Nakasone C, Shinzato T, Akamine M, Haranaga S, et al. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV. J Antimicrob Chemother. 2006;58:1279-82.
23. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32(suppl 1):S9-15.